- Home
- KOD vs DCTH Comparison
KOD vs DCTH Comparison
Compare KOD & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOD
- DCTH
- Stock Information
- Founded
- KOD 2009
- DCTH 1988
- Country
- KOD United States
- DCTH United States
- Employees
- KOD N/A
- DCTH N/A
- Industry
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- DCTH Medical/Dental Instruments
- Sector
- KOD Health Care
- DCTH Health Care
- Exchange
- KOD Nasdaq
- DCTH Nasdaq
- Market Cap
- KOD 454.7M
- DCTH 518.0M
- IPO Year
- KOD 2018
- DCTH N/A
- Fundamental
- Price
- KOD $3.45
- DCTH $12.08
- Analyst Decision
- KOD Hold
- DCTH Strong Buy
- Analyst Count
- KOD 4
- DCTH 4
- Target Price
- KOD $8.00
- DCTH $22.75
- AVG Volume (30 Days)
- KOD 306.7K
- DCTH 387.2K
- Earning Date
- KOD 03-27-2025
- DCTH 03-06-2025
- Dividend Yield
- KOD N/A
- DCTH N/A
- EPS Growth
- KOD N/A
- DCTH N/A
- EPS
- KOD N/A
- DCTH N/A
- Revenue
- KOD N/A
- DCTH $37,205,000.00
- Revenue This Year
- KOD N/A
- DCTH $112.81
- Revenue Next Year
- KOD N/A
- DCTH $61.78
- P/E Ratio
- KOD N/A
- DCTH N/A
- Revenue Growth
- KOD N/A
- DCTH 1701.69
- 52 Week Low
- KOD $2.19
- DCTH $3.70
- 52 Week High
- KOD $11.60
- DCTH $16.97
- Technical
- Relative Strength Index (RSI)
- KOD 28.84
- DCTH 33.06
- Support Level
- KOD $3.59
- DCTH $11.11
- Resistance Level
- KOD $3.89
- DCTH $12.54
- Average True Range (ATR)
- KOD 0.35
- DCTH 0.99
- MACD
- KOD 0.07
- DCTH -0.29
- Stochastic Oscillator
- KOD 4.98
- DCTH 25.06
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.